RMTI为啥被调高rating?# Stock
l*r
1 楼
Rockwell Medical (NASDAQ:RMTI)憇 stock had its "buy" rating reiterated by an
alysts at Craig Hallum in a research report issued to clients and investors
on Friday, AR Network reports. They currently have a $16.00 price objective
on the stock. Craig Hallum抯 price objective indicates a potential upside of
48.56% from the stock抯 previous close.
A number of other firms have also recently commented on RMTI. Analysts at St
ifel Nicolaus raised their price target on shares of Rockwell Medical (NASDA
Q:RMTI) to $18.00 in a research note to investors on Friday. They now have a
揾oldrating on the stock. Separately, analysts at Zacks upgraded shares o
f Rockwell Medical (NASDAQ:RMTI) from an 搖nderperformrating to a 搉eutral
rating in a research note to investors on Tuesday, September 17th. They no
w have a $10.50 price target on the stock. Finally, analysts at Summer Stree
t raised their price target on shares of Rockwell Medical (NASDAQ:RMTI) from
$20.00 to $25.00 in a research note to investors on Thursday, September 5th
. They now have a 揵uyrating on the stock. Two research analysts have rate
d the stock with a hold rating and three have given a buy rating to the comp
any. Rockwell Medical currently has a consensus rating of 揃uyand an avera
ge price target of $16.08.
Shares of Rockwell Medical (NASDAQ:RMTI) traded up 16.94% on Friday, hitting
$10.77. 5,167,101 shares of the company抯 stock traded hands. Rockwell Medi
cal has a one year low of $3.16 and a one year high of $11.80. The stock抯 5
0-day moving average is $7.06 and its 200-day moving average is $4.82. The c
ompany抯 market cap is $429.9 million.
Rockwell Medical, Inc, formerly Rockwell Medical Technologies, Inc, manufact
ures hemodialysis concentrate solutions and dialysis kits, and it sells, dis
tributes and delivers these and other ancillary hemodialysis products primar
ily to hemodialysis providers in the United States, as well as international
ly primarily in Asia, Latin America and Europe.
alysts at Craig Hallum in a research report issued to clients and investors
on Friday, AR Network reports. They currently have a $16.00 price objective
on the stock. Craig Hallum抯 price objective indicates a potential upside of
48.56% from the stock抯 previous close.
A number of other firms have also recently commented on RMTI. Analysts at St
ifel Nicolaus raised their price target on shares of Rockwell Medical (NASDA
Q:RMTI) to $18.00 in a research note to investors on Friday. They now have a
揾oldrating on the stock. Separately, analysts at Zacks upgraded shares o
f Rockwell Medical (NASDAQ:RMTI) from an 搖nderperformrating to a 搉eutral
rating in a research note to investors on Tuesday, September 17th. They no
w have a $10.50 price target on the stock. Finally, analysts at Summer Stree
t raised their price target on shares of Rockwell Medical (NASDAQ:RMTI) from
$20.00 to $25.00 in a research note to investors on Thursday, September 5th
. They now have a 揵uyrating on the stock. Two research analysts have rate
d the stock with a hold rating and three have given a buy rating to the comp
any. Rockwell Medical currently has a consensus rating of 揃uyand an avera
ge price target of $16.08.
Shares of Rockwell Medical (NASDAQ:RMTI) traded up 16.94% on Friday, hitting
$10.77. 5,167,101 shares of the company抯 stock traded hands. Rockwell Medi
cal has a one year low of $3.16 and a one year high of $11.80. The stock抯 5
0-day moving average is $7.06 and its 200-day moving average is $4.82. The c
ompany抯 market cap is $429.9 million.
Rockwell Medical, Inc, formerly Rockwell Medical Technologies, Inc, manufact
ures hemodialysis concentrate solutions and dialysis kits, and it sells, dis
tributes and delivers these and other ancillary hemodialysis products primar
ily to hemodialysis providers in the United States, as well as international
ly primarily in Asia, Latin America and Europe.
